semaglutide development rare but potentially serious vision issues - Semaglutidetablets rybelsus 7 mg semaglutide received FDA approval under the brand name Wegovy The Multifaceted Journey of Semaglutide: From Discovery to Widespread Development

司美格鲁肽 Semaglutide, a groundbreaking GLP-1 receptor agonist, has captured significant attention in recent years, evolving from its initial purpose of treating type 2 diabetes to becoming a pivotal player in weight management and even showing promise in addressing chronic kidney disease作者：JM Friedman·2024·被引用次数：44—In diabetic patients,semaglutide significantly reduced the incidence of cardiovascular events by 26% vs. placebo (23). Weekly semaglutide also .... The development of semaglutide is a testament to scientific innovation, marked by distinct phases, including its early research, the advent of oral formulations, and extensive clinical development.

The Genesis of Semaglutide: Building on Liraglutide

The semaglutide development story is closely intertwined with that of its predecessor, liraglutide. These long-acting GLP-1 analogs were meticulously charted, with researchers focusing on enhancing their therapeutic profiles.作者：S Petta·2025·被引用次数：7—The clinical development ofsemaglutide for patients with MASHhas progressed through comprehensive phase 2 and phase 3 trials, providing robust ... An important advancement in the development of semaglutide involved modifying its structure by replacing liraglutide's C16 fatty acid with a C18 fatty acid. This strategic alteration was key to strengthening albumin binding, a crucial factor in extending the drug's half-life and efficacyThe Discovery and Development of Liraglutide .... This scientific endeavor has led to numerous applications and further research.805-P: Development of a Semaglutide-Releasing Long-Acting ...

Initially, semaglutide was initially developed for treating type 2 diabetes mellitus. Marketed under the brand name Ozempic, it demonstrated remarkable efficacy in managing blood glucose levels. In diabetic patients, semaglutide was observed to significantly reduce the incidence of cardiovascular events by 26% compared to a placebo. This pivotal finding underscored its value beyond glycemic control.

The Rise of Oral Formulations and Broader Applications

A significant milestone in semaglutide development was the creation of an oral formulation. This innovation, particularly the development and approval of Rybelsus (oral semaglutide), marked a new era for oral peptidesMethoddevelopment Andvalidation Of Semaglutide Using Rp. Oral semaglutide is the first oral formulation of a GLP-1RA to be approved in the USA, offering a more convenient administration route for patients. This was achieved by co-formulating semaglutide with sodium N-(8-[2-hydroxybenzoyl]amino)caprylate (SNAC), a permeation enhancerSemaglutide Development. These advancements paved the way for the clinical development of oral semaglutide, with early-phase trials providing a comprehensive overview of its potential.

Beyond its established roles, semaglutide has seen remarkable expansion into the realm of weight management.作者：Y Duan·2022—This review introduces the mechanism, structure, pre-clinical and clinical trials ofsemaglutideand discusses the entire process from the research and ... The development of a semaglutide 2.4 mg once-weekly subcutaneous injection, approved for obesity treatment in 2021 under the brand name Wegovy, resulted in significant mean weight loss of 15–17%. This has led to an "astounding" rise in its usage; between 2019 and 2023, the use of GLP-1 receptor agonists by individuals in the United States with obesity surged by around 700%. The development of semaglutide has thus fundamentally altered the landscape of obesity treatment作者：R Tamayo-Trujillo·2024·被引用次数：71—This minireview describes the molecular mechanisms ofsemaglutideand liraglutide in different metabolic pathways, and its mechanism of action in processes ....

Further pushing the boundaries, semaglutide became the first GLP-1 receptor agonist approved for worsening kidney disease, kidney failure, and death in January 2025. This approval signifies its expanding therapeutic potential and the ongoing exploration of its benefits across various health conditions作者：H Won·2025·被引用次数：4—This review provides a comprehensive overview of theclinical development of oral semaglutide, with a focus on early-phase trials. ... semaglutide .... Moreover, research into semaglutide for patients with MASH (metabolic dysfunction-associated steatohepatitis) has progressed through comprehensive phase 2 and phase 3 trials, indicating promising avenues for its application2025年4月2日—We found thatsemaglutide improves glucose clearance of non-obese, non-diabetic juvenile mice, irrespective of their growth phenotype. However, ....

Ongoing Research and Future Directions

The semaglutide development pipeline remains robust, with ongoing efforts to refine existing products and explore new applications. This includes advancements in long-acting injectable formulations, such as the introduction of novel once-a-month formulation of semaglutide such as IVL3021, developed using IVL-DrugFluidics® technologyR&D pipeline. Explore Lambda's full-service clinical development solutions for semaglutide, supporting GLP-1 RA programs aligned with FDA & EMA guidelines, highlights the comprehensive support available for advancing these drugsWhy Is Semaglutide Suddenly So Popular? - The Endocrine Center.

The global nature of its development is evident, with government records indicating that at least 15 generic versions of semaglutide are being developed for the Chinese market, targeting both diabetes and weight loss. Peptide mapping analysis of synthetic semaglutide is also a critical aspect of this generic development, ensuring quality and comparability.New weight loss pill outperforms oral semaglutide for ...

While the benefits of semaglutide are widely recognized, research also touches upon potential side effects. A new case series has spotlighted rare but potentially serious vision issues in patients taking semaglutide or tirzepatide, underscoring the importance of continued monitoring and research作者：H Won·2025·被引用次数：4—This review provides a comprehensive overview of theclinical development of oral semaglutide, with a focus on early-phase trials. ... semaglutide .... Simultaneously, investigations continue, such as studies showing that semaglutide improves glucose clearance of non-obese, non-diabetic juvenile mice, regardless of growth phenotype, indicating complex interactions within metabolic pathways.

In essence, the development of semaglutide is a dynamic and evolving field. From its initial therapeutic purpose to its widespread adoption in weight management and its emerging role in treating kidney disease, semaglutide represents a significant scientific achievement with a profound impact on public health7天前—In January of 2025,semaglutide became the first GLP-1 receptor agonist approvedfor worsening kidney disease, kidney failure, and death due to .... The sustained global interest and ongoing research promise further innovations and expanded therapeutic possibilities for this remarkable GLP-1 RASemaglutide | GLP-1 RA | Clinical Development.